Myeloma

The latest news, research, and perspectives in multiple myeloma. Myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells that produce monoclonal immunoglobulin. These neoplastic cells result in characteristic clinical features that include bone lytic lesions, hypercalcemia, renal insufficiency, and anemia.

Overview
Advertisement
Advertisement
Melissa BadamoMyeloma | February 27, 2024
The target action date for the FDA’s decision is August 22, 2024.
Read More
Melissa BadamoMyeloma | February 27, 2024
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
Melissa BadamoMyeloma | February 22, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Blood Cancers Today Staff WritersMyeloma | February 21, 2024
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Patrick DalyMyeloma | February 27, 2024
Belamaf, bortezomib, and dexamethasone improved survival versus daratumumab bortezomib, and dexamethasone in myeloma.
Melissa BadamoPrint | February 29, 2024
Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression.
Leah LawrenceMyeloma | February 8, 2024
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Patrick DalyMyeloma | February 7, 2024
The Marketing Authorization Application for linvoseltamab has been submitted and is under review by the EMA.
Melissa BadamoMyeloma | February 12, 2024
A higher percentage of patients receiving daratumumab achieved negative MRD compared with patients who did not.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Patrick DalyMyeloma | January 30, 2024
The CHMP of the European Medicines Agency gave a positive recommendation for the Marketing Authorization approval of ide-cel.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Melissa BadamoMyeloma | February 2, 2024
The study aimed to describe the myeloma-defining events and clinical presentations leading to multiple myeloma diagnosis.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Melissa BadamoMyeloma | February 2, 2024
The study also identified 12 distinct subtypes of myeloma, expanding on previous classifications.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Dwight Macero, PA-C, MSMyeloma | January 8, 2024
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Blood Cancer TalksBlood Cancer Talks | January 10, 2024
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Cecilia BrownPrint | January 3, 2024
Dr. Ghobrial discusses how she entered the field of smoldering myeloma, the racial gap in myeloma research, and more.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Patrick DalyMyeloma | December 20, 2023
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Patrick DalyMyeloma | December 20, 2023
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Patrick DalyMyeloma | December 20, 2023
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Hans Lee, MDMyeloma | December 19, 2023
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
Carlyn Tan, MDMyeloma | December 15, 2023
The study compared characteristics, step up dosing process, and incidence and management of cytokine release syndrome.
Joseph Mikhael, MDMyeloma | December 15, 2023
Dr. Mikhael reflected on how the BOSTON and STOMP studies impacted the myeloma treatment paradigm.
Sagar Lonial, MD, FACPMyeloma | December 15, 2023
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH, the PERSEUS trial, and treating smoldering MM.
Noopur Raje, MDMyeloma | December 18, 2023
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Hamza Hashmi, MDMyeloma | December 14, 2023
Hamza Hashmi, MD, discusses his research at ASH 2023 and whether the results would affect the way he treats elderly patients.
Noopur Raje, MDMyeloma | December 14, 2023
Dr. Raje discussed the Perseus trial, in which most patients were progression-free at four years after a four-drug regimen.
Patrick DalyMyeloma | December 15, 2023
Patients with lenalidomide-refractory MM had significant improvements in health-related QoL and symptoms after cilta-cel.
Patrick DalyMyeloma | December 13, 2023
Cilta-cel was significantly more cost-effective versus DPd or PVd regimens in relapsed or refractory multiple myeloma.
Jeffrey Matous, MDMyeloma | December 13, 2023
Jeffrey Matous, MD, discusses data from the phase Ib MonumenTAL-2 study on talquetamab plus pomalidomide in multiple myeloma.
Ajai Chari, MDMyeloma | December 12, 2023
Ajai Chari, MD, described findings from the MonumenTAL-1 study on talquetamab in patients with myeloma.
Susan Bal, MDMyeloma | December 12, 2023
The study included 84 patients with MM who had a median of four prior lines of therapy.
Nico Gagelmann, MDMyeloma | December 12, 2023
CAR-T therapy, while complex and expensive, has better PFS than autologous or allogenic stem cell transplantation.
Al-Ola Abdallah, MDMyeloma | December 12, 2023
Dr. Al-Ola Abdallah, of the University of Kansas, covers important multiple myeloma data presented at the 2023 ASH meeting.
Patrick DalyMyeloma | December 13, 2023
Doris Hansen, MD, discussed new predictors identified for toxicity and early response in patients with MM on ide-cel.
Melissa BadamoMyeloma | December 9, 2023
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
Melissa BadamoMyeloma | December 9, 2023
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
Patrick DalyMyeloma | February 6, 2024
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
Patrick DalyMyeloma | December 13, 2023
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
Blood Cancers Today Staff WritersMyeloma | February 2, 2024
Joshua Richter, MD, explained this finding and more results from the MyDRUG trial.
Blood Cancers Today Staff WritersMyeloma | December 13, 2023
Rafael Renatino-Canevarolo, PhD, and colleagues explained just how the platform works.
Blood Cancers Today Staff WritersMyeloma | December 13, 2023
Ola Landgren, MD, and colleagues presented details of the new clinical trial at the 65th ASH Annual Meeting and Exposition.
Patrick DalyMyeloma | November 29, 2023
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Patrick DalyMyeloma | November 29, 2023
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Patrick DalyMyeloma | November 29, 2023
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patrick DalyMyeloma | November 28, 2023
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Lorinda Coombs, PhD, MSNMyeloma | November 28, 2023
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Patrick DalyMyeloma | November 16, 2023
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Melissa BadamoMyeloma | November 15, 2023
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Melissa BadamoMyeloma | November 10, 2023
Getting the right care team, treatment, and testing are three steps to empower patients with MM.
Leah SherwoodPrint | November 13, 2023
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
Magdalena Taube, PhDMyeloma | October 27, 2023
Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery.
Blood Cancer TalksBlood Cancer Talks | October 20, 2023
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
Cecilia BrownMyeloma | October 16, 2023
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
Patrick DalyMyeloma | October 10, 2023
A study described several mutations and subclone events that appear to drive relapse in multiple myeloma.
Patrick DalyMyeloma | October 10, 2023
Research suggests that "targeting FcRH5 with CAR T cells may represent a promising therapeutic avenue for MM.”
Patrick DalyMyeloma | October 10, 2023
Researchers identified 1,055 patients diagnosed with MM from 2004 to 2018 who underwent AHSCT within a year of diagnosis.
Joseph Mikhael, MDMyeloma | February 8, 2024
Researchers conducted interviews to gather the perspectives of both clinicians and nurses.
Thomas Martin, MDVideo Insights | October 6, 2023
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
Thomas Martin, MDVideo Insights | October 6, 2023
The panel discusses optimal dosing for teclistamab.
Thomas Martin, MDVideo Insights | October 12, 2023
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
Thomas Martin, MDVideo Insights | October 12, 2023
The panel continues the conversation around toxicity management for bispecific agents.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel compares clinical trial and real-world data for CAR-Ts.
Chadi Nabhan, MD, MBA, FACPMyeloma | October 5, 2023
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
Thomas Martin, MDVideo Insights | October 12, 2023
The panel addresses side effects that are commonly seen in patients receiving bispecifics.
Thomas Martin, MDVideo Insights | October 12, 2023
The panel discusses their personal experience with bispecifics-related REMS programs.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses which patients may not be suitable for CAR T-cell therapy.
Thomas Martin, MDVideo Insights | October 12, 2023
The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.
Blood Cancer TalksBlood Cancer Talks | October 18, 2023
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Cecilia BrownMeeting News | October 2, 2023
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
Joshua Richter, MDMyeloma | February 26, 2024
Dr. Richter discusses the data he presented during the 20th IMS Annual Meeting Exposition.
Cecilia BrownMeeting News | September 28, 2023
Researchers evaluated 1,704 patients with triple-class exposure, including 1,072 who had four-plus previous lines of therapy.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discussed how CAR-T impacts myeloma standard of care.
Thomas Martin, MDVideo Insights | October 13, 2023
The panel provided insights on how they determine whether to give a patient with myeloma CAR T-cell therapy or a bispecific.
Ajai Chari, MDMyeloma | September 25, 2023
The approval of the bispecific antibody is based upon data from the MonumenTAL-1 trial.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The phase III study included patients who received at least one prior line of therapy.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Blood Cancers Today Staff WritersMyeloma | February 8, 2024
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Leah LawrenceMyeloma | February 8, 2024
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Thomas Martin, MDVideo Insights | October 13, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Cecilia BrownMyeloma | September 4, 2023
Researchers examined tumor-intrinsic factors that promote multiple myeloma antigen escape.
Ajay Nooka, MD, FACPMyeloma | August 28, 2023
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Cecilia BrownMyeloma | August 22, 2023
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Cecilia BrownMyeloma | August 14, 2023
The bispecific antibody received Breakthrough Therapy Designation from the FDA in November 2022.
Cecilia BrownMyeloma | August 14, 2023
There was no significant difference in the number of mutations present at diagnosis between the two groups of patients.
Cecilia BrownMyeloma | August 15, 2023
The researchers used a cumulative deficit approach to calculate a frailty index score at diagnosis and at landmark intervals.
Cecilia BrownMyeloma | September 19, 2023
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
Cecilia BrownMyeloma | August 9, 2023
More than one-quarter of the patients required a dose reduction due to adverse events.
Leah SherwoodMyeloma | August 2, 2023
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Shambavi Richard, MDMyeloma | July 24, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Claudio Cerchione, MD, PhDMyeloma | September 5, 2023
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Cecilia BrownMyeloma | July 4, 2023
Patients with clonal plasma cells in the autograft had a significantly lower MRD-negative CR rate after transplant.
Cecilia BrownMyeloma | July 3, 2023
The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide.
Cecilia BrownMyeloma | July 27, 2023
The supplemental BLA submission is supported by data from the CARTITUDE-4 study.
Cecilia BrownMyeloma | July 18, 2023
Researchers used a simulated partitioned survival model to compare overall survival among three treatment strategies.
Cecilia BrownMyeloma | June 27, 2023
A recent study showed significant differences in OS based on the t(4;14) translocation breakpoint area in MM.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Blood Cancer TalksBlood Cancer Talks | June 29, 2023
The hosts discuss the latest data on CAR-T from the summer conference season.
Leah SherwoodMyeloma | June 26, 2023
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Leah SherwoodMyeloma | August 14, 2023
The FDA has put a clinical hold on the investigational new drug CART-ddBCMA.
Blood Cancer TalksBlood Cancer Talks | August 15, 2023
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
Thomas Martin, MDMeeting News | June 12, 2023
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
Cecilia BrownMyeloma | September 5, 2023
The response rates seen with talquetamab in the trial were "very impressive," Dr. Schinke said.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
Cecilia BrownMyeloma | September 5, 2023
The study evaluated teclistamab in patients with relapsed or refractory multiple myeloma.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
Cecilia BrownMyeloma | September 5, 2023
The phase II study evaluated linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed or refractory MM.
Chadi Nabhan, MD, MBA, FACPMyeloma | September 5, 2023
Dr. Mohan discusses her 2023 ASCO Annual Meeting presentation with Chadi Nabhan, MD, MBA, FACP.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
Patients treated with the higher dose had higher overall response rates.
Leah SherwoodMyeloma | October 20, 2023
Dr. Bansal and colleagues presented the results of the study at the 2023 ASCO Annual Meeting.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
The overall response rate was 87.8% with 73% of patients achieving complete response.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
The median time from last dose of selinexor to anti-BCMA therapy was eight weeks.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
Improvement of nontarget lesions was noted in five of 25 patients (20%).
Leah SherwoodMyeloma | September 5, 2023
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
At the ASCO meeting, researchers presented results of the trial with 22 months of follow-up.
Blood Cancers Today Staff WritersMyeloma | September 5, 2023
The ongoing, long-term CARTITUDE study will continue to follow these patients for safety and survival.
Leah SherwoodMyeloma | September 5, 2023
Sikander Ailawadhi, MD, speaks about the Mayo Clinic's efforts to address health care disparities.
Leah LawrenceMyeloma | February 8, 2024
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Cecilia BrownMyeloma | May 30, 2023
Bone marrow assessment of MRD is “prognostic for survival”, but bone marrow remains hypocellular at month one after ...
Cecilia BrownMyeloma | May 30, 2023
A recent study suggests the initial T-cell landscape could shape responses to bispecific T-cell engagers in MM.
Cecilia BrownMyeloma | May 30, 2023
The study included patients from the National Cancer Research Institute Myeloma XI trial.
Cecilia BrownMyeloma | May 30, 2023
The researchers assigned points to multiple factors to develop a risk score.
Cecilia BrownMyeloma | May 30, 2023
A new study suggests there is an “optimal” dose of carfilzomib for patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | May 30, 2023
The study was a retrospective pooled analysis of multicenter global clinical trials that submitted data to the US FDA.
Blood Cancer TalksBlood Cancer Talks | August 1, 2023
The episode was inspired by an article titled “The Underrepresented Majority" by Andrés Gómez-De León, MD.
Blood Cancer TalksBlood Cancer Talks | August 1, 2023
Dr. Gertz and the hosts provide an overview of risk-stratification approaches and clinical trials in smoldering MM.
Blood Cancer TalksBlood Cancer Talks | July 19, 2023
Dr. Costa discusses the multiple uses of MRD in MM.
Sagar Lonial, MD, FACPViewpoints | May 15, 2023
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
Leah SherwoodMyeloma | June 9, 2023
The FDA has set a target action date of December 16, 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Thomas Martin, MDVideo Insights | May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Larysa Sanchez, MDMyeloma | May 12, 2023
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM. 
Thomas Martin, MDVideo Insights | May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | May 5, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Leah SherwoodMyeloma | February 8, 2024
Dr. Tauro speaks about her presentation on novel strategies to overcome chemotherapy resistance in MM at AACR 2023.
Cecilia BrownMeeting News | April 20, 2023
The design of the bispecific antibody aims to overcome challenges with cytokine release syndrome.
Cecilia BrownMyeloma | April 14, 2023
The study used genomics to determine how often high-risk events "are missed at diagnosis and selected at relapse."
Cecilia BrownMyeloma | April 14, 2023
Novel agents did not significantly improve outcomes over conventional therapies in certain patients.
Leah LawrenceMyelodysplastic Syndromes | April 17, 2023
Novel targets are under investigation in several types of hematologic malignancies.
Sandy Wong, MDMyeloma | March 29, 2023
Dr. Wong hopes to see an expansion in the availability of new and novel treatments for myeloma.
Cecilia BrownMyeloma | March 28, 2023
The study included patients who had disease progression after participating in a bispecific antibody clinical trial.
Shambavi Richard, MDMyeloma | March 27, 2023
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure. 
Sandy Wong, MDMyeloma | March 22, 2023
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Cecilia BrownMyeloma | March 22, 2023
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Sandy Wong, MDMyeloma | March 28, 2023
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Leah SherwoodMyeloma | April 12, 2023
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Cecilia BrownMyeloma | March 15, 2023
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MDMyeloma | March 28, 2023
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Cecilia BrownMyeloma | May 11, 2023
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Cecilia BrownMyeloma | March 10, 2023
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Sagar Lonial, MD, FACPMyeloma | March 6, 2023
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Cecilia BrownMyeloma | April 12, 2023
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Cecilia BrownMyeloma | March 6, 2023
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
Leah SherwoodMyeloma | February 27, 2023
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
Leah SherwoodMyeloma | April 12, 2023
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Leah SherwoodPrint | February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Leah SherwoodMyeloma | April 12, 2023
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Cecilia BrownMyeloma | April 12, 2023
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Leah SherwoodMyeloma | February 1, 2023
A triplet may improve PFS over lenalidomide alone in patients with multiple myeloma who underwent induction and AHSCT.
Cecilia BrownMyeloma | April 12, 2023
A new method to detect MRD in peripheral blood had an “unprecedented sensitivity” level in multiple myeloma.
Cecilia BrownMyeloma | February 1, 2023
Adding isatuximab to carfilzomib and dexamethasone improved PFS in multiple myeloma, regardless of relapse time.
Cecilia BrownMyeloma | March 8, 2023
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Cecilia BrownMyeloma | February 7, 2023
The FDA received a Biologics License Application for the use of talquetamab in patients with R/R multiple myeloma.
Leah SherwoodPrint | February 24, 2023
Elranatamab was granted Breakthrough Therapy Designation by the U.S. FDA for relapsed/refractory multiple myeloma.
Leah SherwoodPrint | February 1, 2023
The U.S. FDA has accepted for review and filed the New Drug Application for motixafortide.
Cecilia BrownMyeloma | March 8, 2023
Adding vorinostat to lenalidomide maintenance therapy did not improve survival over lenalidomide in multiple myeloma.
Shambavi Richard, MDVideo Insights | March 24, 2023
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Ajai Chari, MDVideo Insights | March 3, 2023
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
Leah SherwoodMeeting News | December 27, 2022
Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications.
Leah SherwoodMyeloma | February 8, 2024
Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study.
Amrita Krishnan, MD, FACPPrint | May 30, 2023
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Chadi Nabhan, MD, MBA, FACPVideo Insights | February 1, 2023
Robert Orlowski, MD, PhD, discusses bispecific antibodies and novel targets in myeloma with Chadi Nabhan, MD, MBA, FACP.
Chadi Nabhan, MD, MBA, FACPMyeloma | January 10, 2023
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.
Chadi Nabhan, MD, MBA, FACPVideo Insights | January 10, 2023
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
Cecilia BrownMyeloma | December 14, 2022
Patients with heavily pretreated multiple myeloma who received bispecific CAR T-cells had an OS rate of 83.9%.
Cecilia BrownVideo Insights | January 11, 2023
Sandy Wong, MD, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory MM.
Cecilia BrownMyeloma | December 12, 2022
The phase I UNIVERSAL trial showed allogeneic CAR-T therapy led to “significant and durable responses” in patients with ...
Leah LawrenceMyeloma | December 10, 2022
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Leah LawrenceMyeloma | December 10, 2022
Selinexor combinations had moderate efficacy in real-world patients with relapsed or refractory multiple myeloma.
Kerri FitzgeraldMyeloma | December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Cecilia BrownMyeloma | December 10, 2022
BCMA-directed CAR-T led to a CR in 75% in relapsed/refractory multiple myeloma who received allogeneic HSCT.
Cecilia BrownMyeloma | December 10, 2022
A new study suggests many interventional phase III clinical trials in myeloma didn't clearly define high-risk disease.
Leah LawrenceMeeting News | December 8, 2022
More genetic information is needed to investigate the link between racial ancestry and outcomes in multiple myeloma.
Leah LawrenceMeeting News | December 8, 2022
Selinexor plus rituximab, gemcitabine, cisplatin and dexamethasone had encouraging activity in patients with B-cell lymphoma.
Cecilia BrownMyeloma | February 8, 2024
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
Cecilia BrownMyeloma | December 2, 2022
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Leah SherwoodMyeloma | February 1, 2023
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Cecilia BrownMyeloma | February 7, 2023
AgenT-797 is a scalable, off-the-shelf therapy that retains potent cytotoxicity after cryopreservation.
Cecilia BrownMyeloma | July 17, 2023
Findings support daratumumab plus lenalidomide and dexamethasone treatment for at least 18 months in MM...
Cecilia BrownMyeloma | November 16, 2022
Ciltacabtagene autoleucel led to responses in 61.5% of patients with multiple myeloma...
Leah SherwoodMyeloma | November 15, 2022
The phase III DREAMM-3 trial did not meet its primary endpoint...
Cecilia BrownTransplantation & Cellular Therapy | November 15, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Leah SherwoodMyeloma | December 27, 2022
The FDA has granted accelerated approval for the use of teclistamab in adults with relapsed or refractory multiple myeloma.
Leah SherwoodMyeloma | November 17, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Kerri FitzgeraldMyeloma | November 15, 2022
A single infusion of ciltacabtagene autoleucel led to impressive overall response rates...
Kerri FitzgeraldMyeloma | November 16, 2022
A new study suggests the current reference intervals for serum free light chain concentrations...
Kerri FitzgeraldMyeloma | November 16, 2022
Talquetamab demonstrated “highly promising efficacy” in heavily pretreated patients with...
Cecilia BrownMyeloma | November 16, 2022
The phase I/II MajesTEC-1 study demonstrated that teclistamab produced a high rate of deep...
Thomas Martin, MDMyeloma | May 12, 2023
We are entering the great era of immunotherapy in multiple myeloma.
Cecilia BrownMyeloma | November 16, 2022
The European Commission (EC) has granted marketing authorization for melphalan flufenamide...
Cecilia BrownMyeloma | November 16, 2022
The European Commission granted Conditional Marketing Authorization for teclistamab as a...
Leah SherwoodMyeloma | November 28, 2022
The committee overwhelmingly voted that melphalan flufenamide has not demonstrated benefit...
Leah SherwoodMyeloma | November 16, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Kerri FitzgeraldMyeloma | November 22, 2022
Antibiotic prophylaxis should be considered an option for patients with newly diagnosed multiple myeloma...
Kerri FitzgeraldMyeloma | November 16, 2022
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
Leah SherwoodMyeloma | November 16, 2022
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Leah SherwoodMeeting News | November 22, 2022
Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...
Cecilia BrownMyeloma | November 22, 2022
Ciltacabtagene autoleucel led to an overall response rate of nearly 98% in heavily pretreated...
Cecilia BrownMyeloma | November 22, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Cecilia BrownMyeloma | November 22, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Cecilia BrownMyeloma | November 16, 2022
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS.
Leah SherwoodMeeting News | November 22, 2022
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
Leah SherwoodMyeloma | May 12, 2023
A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses" in CARTITUDE-2’s cohort A.
Leah SherwoodMyeloma | November 16, 2022
The data were from the phase III DETERMINATION trial...
Leah SherwoodMyeloma | November 16, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Cecilia BrownMeeting News | November 22, 2022
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Leah SherwoodAcute Myeloid Leukemia | November 16, 2022
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
Leah SherwoodMyeloma | November 16, 2022
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
Leah SherwoodMyeloma | November 22, 2022
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
Cecilia BrownMyeloma | November 22, 2022
The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...
Leah SherwoodMyeloma | November 22, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
Leah SherwoodMyeloma | November 22, 2022
The genetic signature consists of the genes WNT10A, DUSP1, and ETV7...
Leah SherwoodMyeloma | November 22, 2022
QXL138AM is a masked immunocytokine comprised of a CD138-targeted antibody fused with...
Leah LawrenceMyeloma | November 22, 2022
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
Kerri FitzgeraldAcute Myeloid Leukemia | November 16, 2022
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Leah LawrenceChronic Lymphocytic Leukemia | November 16, 2022
LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker.
Leah SherwoodMyeloma | November 16, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Leah SherwoodMyeloma | November 16, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Leah LawrenceMyeloma | November 22, 2022
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
Leah LawrenceMyeloma | November 22, 2022
IgD myeloma constitutes about 1% of myelomas and has worse prognosis than other subtypes...
Kerri FitzgeraldMyeloma | November 16, 2022
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
Leah LawrenceMyeloma | November 16, 2022
The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma...
Leah LawrenceMyeloma | February 3, 2023
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Kerri FitzgeraldMyeloma | February 3, 2023
Authors provide a case that demonstrates the real-world challenges of managing older, frail adults with newly diagnosed MM.
Kerri FitzgeraldMyeloma | February 3, 2023
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
Leah LawrenceMyeloma | February 3, 2023
A small study observed a link between BMI and progression of monoclonal gammopathy of undetermined significance.
Leah LawrenceMyeloma | February 3, 2023
However, the three-drug combination improved survival in the relapsed/refractory setting.
Leah LawrenceMyeloma | February 3, 2023
Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial
Leah LawrenceMyeloma | February 3, 2023
A study has identified a very high prevalence of all monoclonal gammopathies in high-risk individuals aged 50 years or older.
Leah LawrenceMyeloma | November 14, 2022
A study identified differences in molecular features that may drive clinical disparities seen in patients with myeloma.
Leah LawrenceMyeloma | November 14, 2022
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Ariel DeMaioMyeloma | November 14, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Leah LawrenceMyeloma | November 14, 2022
A phase I study is underway to assess ALLO-605.
Leah LawrenceMyeloma | November 14, 2022
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Leah LawrenceMyeloma | November 14, 2022
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Leah LawrenceMyeloma | November 14, 2022
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
Sabrina AhleMyeloma | November 14, 2022
New legislation would set time limits around FDA accelerated approvals.
Sabrina AhleMyeloma | November 14, 2022
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Sabrina AhleMyeloma | November 14, 2022
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Leah LawrenceTransplantation & Cellular Therapy | February 1, 2023
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Patrick DalyMyeloma | November 14, 2022
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Ariel DeMaioAggressive B-Cell Lymphoma | February 1, 2023
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Brandon MayMyeloma | November 14, 2022
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Sabrina AhleMyeloma | November 14, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Sagar Lonial, MD, FACPMyeloma | November 14, 2022
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Jacob Laubach, MD, MPPMyeloma | November 14, 2022
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Sabrina AhleMyeloma | February 1, 2023
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes.
Sabrina AhleMantle Cell Lymphoma | February 2, 2023
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sagar Lonial, MD, FACPMyeloma | February 2, 2023
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | November 15, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Sabrina AhleMyeloma | November 14, 2022
Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ...
Sagar Lonial, MD, FACPMyeloma | January 21, 2022
I welcome you to the first edition of Blood Cancers Today.
Advertisement
Advertisement
Latest News

March 1, 2024